> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Committee to Review PTC Therapeutics NDA
- URL: https://www.fdaweb.com/advisory-committee-to-review-ptc-therapeutics-nda/
- Published: 2017-08-23T12:00:00.000Z
- Updated: 2026-09-14T22:42:53.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139453

*Federal Register* notice: FDA has announced a 9/28 Peripheral and Central Nervous System Drugs Advisory Committee meeting. Panel members will discuss and vote on a PTC Therapeutics NDA for ataluren for oral suspension, indicated for treating patients with dystrophinopathy due to a nonsense mutation in the dystrophin gene. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-08-23/pdf/2017-17856.pdf?ref=fdaweb.com).